Midcap biotech companies spent $746.8 million on research and development in the third quarter of 2012, an increase from $621.1 million in the same period of 2011, according to a report from GlobalData. The focus of research programs is cancer treatment, "which is driving peer group R&D expenses higher," an analyst said.
Report: Midcap biotechs boost R&D investment in Q3 2012
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Attest Health Care Advisors
|Vice President of Finance||
Urban Health Plan, Inc.